MipSalus closes a private placement

November 2020: MipSalus closes a private placement from private investors.

Inborn Errors of Metabolism Drug Development Conference

March 2020: CSO Klaus Gregorius will present MipSalus’ groundbreaking yet simple solution to treating PKU at the Inborn Errors of Metabolism Drug Development Conference. With the new treatment which MipSauls is currently developed, PKU patients will take the phenylalanine binding drug Phelimin before eating. As Phelimin binds phenylalanine and transports it out of the body, it enables PKU-patients to consume food high in protein. Phelimin thus transforms children and adults with PKU from patients on a strict protein-limited diet to people eating a normal diet.

At the conference, which takes place in Boston, US, over 80 inherited metabolic disease drug developers and Key Opinion Leaders will explore how key challenges prohibiting accelerated drug development are being addressed.

FDA grants Phelimin an Orphan Drug Designation

February 2020: MipSalus has reached yet another Phelimin milestone with the Orphan Drug Designation granted by U.S. Food & Drug Administration, FDA. The Orphan Drug Designation was awarded based on the scientific evidence produced by MipSalus and it entails a range of benefits that apply to all stages of the development of Phelimin. The decision is published on the FDA website.